Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Epidemiologic studies about DG show heterogeneous data: in a study, among type 1 and type 2 diabetic patients with GI symptoms, the incidence of documented gastroparesis was 60% [35], while a more recent community-based study showed a ten-year cumulative incidence of gastroparesis of 5.2% in type 1 diabetes versus 1% in type 2 diabetes [36].
Whilst GE is often delayed in gastroparesis, the entity of motility alteration has a poor correlation with the severity of symptoms [37].
Histological findings in both diabetic and non-diabetic gastroparetic patients showed loss of interstitial cells of Cajal (ICCs) and ganglion cells, fibrosis of the pylorus and lymphocytic infiltration around myenteric plexus [37].
Notably, gastroparesis and FD show the same histopathologi…